MedTrace Logo

Study to Evaluate the Safety and Efficacy of Minocycline Ointment in Subjects With Inflamed Meibomian Gland Dysfunction

NCT03888378 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 270

Last updated 2021-03-05

No results posted yet for this study

Summary

To evaluate the efficacy and safety of two strengths of HY02 Ointment versus Vehicle administered twice daily for twelve weeks in subjects with a diagnosis of Inflamed Meibomian Gland Dysfunction.

Conditions

  • Meibomian Gland Dysfunction
  • MGD-Meibomian Gland Dysfunction

Interventions

DRUG

0.3% Topical Minocycline Ointment

0.3% Topical Minocycline ointment to treat inflamed Meibomian Gland Dysfunction

DRUG

1% Topical Minocycline Ointment

1% Topical Minocycline ointment to treat inflamed Meibomian Gland Dysfunction

OTHER

Topical Vehicle Ointment

Topical vehicle ointment to treat inflamed Meibomian Gland Dysfunction

Sponsors & Collaborators

  • Hovione Scientia Limited

    lead INDUSTRY

Principal Investigators

  • George Magrath, MD · Hovione Scientia Limited

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-02
Primary Completion
2020-09-18
Completion
2021-02-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03888378 on ClinicalTrials.gov